BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 34226552)

  • 1. Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma.
    van Hooren L; Vaccaro A; Ramachandran M; Vazaios K; Libard S; van de Walle T; Georganaki M; Huang H; Pietilä I; Lau J; Ulvmar MH; Karlsson MCI; Zetterling M; Mangsbo SM; Jakola AS; Olsson Bontell T; Smits A; Essand M; Dimberg A
    Nat Commun; 2021 Jul; 12(1):4127. PubMed ID: 34226552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells.
    Kosaka A; Ohkuri T; Okada H
    Cancer Immunol Immunother; 2014 Aug; 63(8):847-57. PubMed ID: 24878890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Local convection-enhanced delivery of an anti-CD40 agonistic monoclonal antibody induces antitumor effects in mouse glioma models.
    Shoji T; Saito R; Chonan M; Shibahara I; Sato A; Kanamori M; Sonoda Y; Kondo T; Ishii N; Tominaga T
    Neuro Oncol; 2016 Aug; 18(8):1120-8. PubMed ID: 26917236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Induction of Tertiary Lymphoid Structures in Cancer Through Stromal Remodeling.
    Johansson-Percival A; Ganss R
    Front Immunol; 2021; 12():674375. PubMed ID: 34122434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiotherapy and CD40 Activation Separately Augment Immunity to Checkpoint Blockade in Cancer.
    Rech AJ; Dada H; Kotzin JJ; Henao-Mejia J; Minn AJ; Twyman-Saint Victor C; Vonderheide RH
    Cancer Res; 2018 Aug; 78(15):4282-4291. PubMed ID: 29844122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD40 ligation in vivo can induce T cell independent antitumor effects even against immunogenic tumors.
    Rakhmilevich AL; Buhtoiarov IN; Malkovsky M; Sondel PM
    Cancer Immunol Immunother; 2008 Aug; 57(8):1151-60. PubMed ID: 18214476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Tertiary Lymphoid Structures for Tumor Immunotherapy.
    Tang H; Qiu X; Timmerman C; Fu YX
    Methods Mol Biol; 2018; 1845():275-286. PubMed ID: 30141019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity.
    Morrison AH; Diamond MS; Hay CA; Byrne KT; Vonderheide RH
    Proc Natl Acad Sci U S A; 2020 Apr; 117(14):8022-8031. PubMed ID: 32213589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tertiary lymphoid structures improve immunotherapy and survival in melanoma.
    Cabrita R; Lauss M; Sanna A; Donia M; Skaarup Larsen M; Mitra S; Johansson I; Phung B; Harbst K; Vallon-Christersson J; van Schoiack A; Lövgren K; Warren S; Jirström K; Olsson H; Pietras K; Ingvar C; Isaksson K; Schadendorf D; Schmidt H; Bastholt L; Carneiro A; Wargo JA; Svane IM; Jönsson G
    Nature; 2020 Jan; 577(7791):561-565. PubMed ID: 31942071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts.
    Rodriguez AB; Peske JD; Woods AN; Leick KM; Mauldin IS; Meneveau MO; Young SJ; Lindsay RS; Melssen MM; Cyranowski S; Parriott G; Conaway MR; Fu YX; Slingluff CL; Engelhard VH
    Cell Rep; 2021 Jul; 36(3):109422. PubMed ID: 34289373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model.
    Luheshi NM; Coates-Ulrichsen J; Harper J; Mullins S; Sulikowski MG; Martin P; Brown L; Lewis A; Davies G; Morrow M; Wilkinson RW
    Oncotarget; 2016 Apr; 7(14):18508-20. PubMed ID: 26918344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tertiary Lymphoid Structures as a Predictive Biomarker of Response to Cancer Immunotherapies.
    Trüb M; Zippelius A
    Front Immunol; 2021; 12():674565. PubMed ID: 34054861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tertiary Lymphoid Structures in the Central Nervous System: Implications for Glioblastoma.
    van de Walle T; Vaccaro A; Ramachandran M; Pietilä I; Essand M; Dimberg A
    Front Immunol; 2021; 12():724739. PubMed ID: 34539661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. STINGing the Tumor Microenvironment to Promote Therapeutic Tertiary Lymphoid Structure Development.
    Filderman JN; Appleman M; Chelvanambi M; Taylor JL; Storkus WJ
    Front Immunol; 2021; 12():690105. PubMed ID: 34054879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD86
    Wennhold K; Thelen M; Lehmann J; Schran S; Preugszat E; Garcia-Marquez M; Lechner A; Shimabukuro-Vornhagen A; Ercanoglu MS; Klein F; Thangarajah F; Eidt S; Löser H; Bruns C; Quaas A; von Bergwelt-Baildon M; Schlößer HA
    Cancer Immunol Res; 2021 Sep; 9(9):1098-1108. PubMed ID: 34155067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tertiary lymphoid structures and B lymphocytes in cancer prognosis and response to immunotherapies.
    N J; J T; Sl N; Gt B
    Oncoimmunology; 2021 Mar; 10(1):1900508. PubMed ID: 33854820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic Agonistic Anti-CD40 Treatment of Tumor-Bearing Mice Modulates Hepatic Myeloid-Suppressive Cells and Causes Immune-Mediated Liver Damage.
    Medina-Echeverz J; Ma C; Duffy AG; Eggert T; Hawk N; Kleiner DE; Korangy F; Greten TF
    Cancer Immunol Res; 2015 May; 3(5):557-66. PubMed ID: 25637366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Intratumoral B cells and tertiary lymphoid structures are biomarkers of survival and immunotherapy responses].
    Fridman WH; Petitprez F; Sautes-Fridman C
    Bull Cancer; 2020 Apr; 107(4):403-404. PubMed ID: 32284150
    [No Abstract]   [Full Text] [Related]  

  • 19. Tertiary Lymphoid Structures and B cells: Clinical impact and therapeutic modulation in cancer.
    Sautès-Fridman C; Verneau J; Sun CM; Moreira M; Chen TW; Meylan M; Petitprez F; Fridman WH
    Semin Immunol; 2020 Apr; 48():101406. PubMed ID: 33248905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas.
    Flores-Toro JA; Luo D; Gopinath A; Sarkisian MR; Campbell JJ; Charo IF; Singh R; Schall TJ; Datta M; Jain RK; Mitchell DA; Harrison JK
    Proc Natl Acad Sci U S A; 2020 Jan; 117(2):1129-1138. PubMed ID: 31879345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.